Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in Advanced Urothelial Tract Transitional Cell Carcinoma
NCT00004856Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2002
- Primary completion
- Jul 2002
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Jul 2002; status: terminated.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00004856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004856.